Cargando…
Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Sociedade Brasileira de Endocrinologia e Metabologia
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697647/ http://dx.doi.org/10.20945/2359-3997000000520 |
| _version_ | 1785154793680928768 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10697647 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Sociedade Brasileira de Endocrinologia e Metabologia |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106976472023-12-06 Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment Arch Endocrinol Metab Erratum Sociedade Brasileira de Endocrinologia e Metabologia 2022-09-08 /pmc/articles/PMC10697647/ http://dx.doi.org/10.20945/2359-3997000000520 Text en https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Erratum Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment |
| title | Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment |
| title_full | Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment |
| title_fullStr | Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment |
| title_full_unstemmed | Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment |
| title_short | Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment |
| title_sort | peptide receptor radionuclide therapy (prrt) in radioiodine-refractory thyroid cancer: a case report of significant response to lu177 dota-tate treatment |
| topic | Erratum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697647/ http://dx.doi.org/10.20945/2359-3997000000520 |